João Pedreira Duprat Neto

Accuracy of PET/CT in the diagnosis of pelvic lymph node metastases in melanoma: A subgroup analysis of the prospective, randomised, phase III Evaluation of groin lymphadenectomy extent for metastatic melanoma (EAGLE-FM) trial

Michael J. Russell, Louise Emmett, Barbara Perić, Robyn P.M. Saw et autres

au, si, br, gb, nl, it (code pays fourni par la source)

NEOSENT: Neoadjuvant anti-PD-1 therapy for patients with high-risk clinical stage II melanoma with a scheduled sentinel lymph node biopsy.

Matheus M. Lôbo, André Sapata Molina, Ivan Santos Filho, Manoel Jesus Pinheiro Coelho et autres

TPS9609 Background: High-risk clinical stage II melanoma patients are already indicated for adjuvant anti-PD-1 therapy, regardless of the sentinel lymph node biopsy (SLNB) result, due to the high risk of relapse associated with pathological stages IIB/IIC or IIIC. Additionally, sentinel lymph node …

br (code pays fourni par la source)

ctDNA versus 18F-FDG PET-CT in predicting long-term disease control in patients with advanced melanoma undergoing immune checkpoint blockade therapy.

Karina Miranda Santiago, Nathália de Angelis de Carvalho, Rafael Canfield Brianese, Clóvis Antônio Lopes Pinto et autres

9559 Background: Imaging remains the gold standard for assessing response to systemic immunotherapy in patients with advanced melanoma. Several studies have demonstrated a strong correlation between metabolic response evaluation using 18F-FDG PET-CT and long-term prognosis in patients with advanced melanoma treated with …

br (code pays fourni par la source)

Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma

Serigne Lo, Caroline A. Gjorup, Annette Hougaard Chakera, Lisbet Rosenkrantz Hölmich et autres

Importance: The Melanoma Institute Australia (MIA) sentinel node (SN) metastasis risk calculator provides estimates of positivity for individual patients based on 6 standard clinicopathological parameters and the full 6-parameter model has been externally validated previously using US data. However, given its geographically …

au, dk, gb, se, us, br, nz, nl (code pays fourni par la source)

FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma

Li Zhou, Edward Hsiao, Zeynep Eroglu, Shahneen Kaur Sandhu et autres

BACKGROUND: Neoadjuvant immunotherapy has become the new standard of care for stage III melanoma. This study sought to describe the metabolic changes seen with fludeoxyglucose-18-positron emission tomography (FDG-PET) following neoadjuvant immunotherapy in patients with melanoma and explore associations with pathological response and …

au, cn, br, us, ru (code pays fourni par la source)

Challenges of Treating Merkel Cell Carcinoma in Brazil

Matheus de Melo Lobo, João Pedreira Duprat Neto, Milton Jose Barros, Rodrigo Ramella Munhoz et autres

Treating Merkel cell carcinoma (MCC) presents significant challenges due to the disease's aggressive nature, low survival rates, and rising incidence over the last decades. Despite advancements in treatment, numerous barriers persist, especially in developing countries. Brazil, home to half of South America's …

br, us (code pays fourni par la source)

Evaluation of the applicability of immunohistochemical expression of Ki-67 as a prognostic factor in cutaneous melanoma

V.C. Siervi, Livia Prôa Felippe, R. Nahime, B.D. Assis et autres

Background: Despite advances in diagnosis and clinical management, prognostic stratification in melanoma still faces significant challenges. Melanoma accounts for only 1% of skin cancers but is among the most lethal. Prognostic factors such as Breslow thickness and ulceration are established; however, they …

br (code pays fourni par la source)

Analysis of the expression of cytokines and chemokines, platelet‐leukocyte aggregates, sCD40L and sCD62P in cutaneous melanoma

Rogério Luiz dos Santos, Mário Rino Martins, Valéria Lobo Tavares, João Pedreira Duprat Neto et autres

BACKGROUND: Cutaneous melanoma (CM) is a malignancy with a variable incidence worldwide and a poor advanced-stage prognosis. Melanoma growth is closely associated with the immune system. METHODS: A cross-sectional study was performed on CM patients admitted at the Hospital de Cancer de …

br (code pays fourni par la source)

A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts

Laura Bravo, Joana F F Simoes, Victor Roth Cardoso, Adewale Adisa et autres

BACKGROUND: Pulmonary complications are the most common cause of death after surgery. This study aimed to derive and externally validate a novel prognostic model that can be used before elective surgery to estimate the risk of postoperative pulmonary complications and to support …

Brazilian Society of Surgical Oncology recommendations on Merkel cell carcinoma surgical treatment

Matheus de Melo Lobo, Alberto Julius Alves Wainstein, Aldo Vieira Barros, Alexandre Ferreira Oliveira et autres

BACKGROUND: Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer with poor 5-year survival rates. Surgery and radiation are the current first-line treatments for local and nodal disease. OBJECTIVES: The Brazilian Society of Surgical Oncology developed this document aiming to guide …

us, br (code pays fourni par la source)

Combined EORTC FDG-PET/CT and RECIST 1.1 response criteria and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.

Monique Celeste Tavares, João Paulo da Silveira Nogueira Lima, José Augusto Rinck, André Sapata Molina et autres

9590 Background: Accurate identification of pathological response to neoadjuvant therapy for clinical stage III melanoma before surgery may allow us to better tailor the treatment. RECIST 1.1 has shown poor concordance rates with pathological responses and EORTC FDG-PET/CT response criteria using SUV …

br, au (code pays fourni par la source)

Analysis of neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma using the SWOG S1801 event-free survival definition.

Monique Celeste Tavares, João Paulo da Silveira Nogueira Lima, Daniel López García, André Sapata Molina et autres

e21563 Background: Perioperative pembrolizumab to advanced melanoma, as shown SWOG S1801 trial, was associated with a longer event-free survival (EFS) than those who received adjuvant pembrolizumab (EFS at 2y: 72% vs 49%, respectively). EFS, as defined in this trial, encompasses important factors …

br (code pays fourni par la source)